1. Atopic dermatitis in adolescents. effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in italy
- Author
-
Maddalena Napolitano, Maria Concetta Fargnoli, Teresa Grieco, Gabriella Fabbrocini, Myriam Zucca, Katharina Hansel, Giovanni Pellacani, Cataldo Patruno, Viviana Piras, Giampiero Girolomoni, Maria Esposito, Elettra Antonelli, Giacomo Dal Bello, Luca Stingeni, Stingeni, L., Hansel, K., Antonelli, E., Bello, G. D., Patruno, C., Napolitano, M., Fabbrocini, G., Grieco, T., Pellacani, G., Fargnoli, M. C., Esposito, M., Piras, V., Zucca, M., and Girolomoni, G.
- Subjects
atopic dermatiti ,Male ,Moderate to severe ,Pediatrics ,medicine.medical_specialty ,real-world ,adolescents ,atopic dermatitis ,COVID-19 ,dupilumab ,Adolescent ,Antibodies, Monoclonal, Humanized ,Female ,Humans ,Pandemics ,SARS-CoV-2 ,Severity of Illness Index ,Treatment Outcome ,Dermatitis, Atopic ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Dermatitis ,Dermatology ,Asymptomatic ,Antibodies ,Atopic ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Monoclonal ,Pandemic ,medicine ,Humanized ,business.industry ,General Medicine ,Atopic dermatitis ,medicine.disease ,Dupilumab ,Clinical trial ,030220 oncology & carcinogenesis ,medicine.symptom ,business ,Human - Abstract
Dupilumab showed significant improvement of adolescent atopic dermatitis (AD) signs and symptoms in clinical trials, with a good safety profile. Herein we report the real-word effectiveness and safety of dupilumab in adolescents with moderate to severe AD from January to October 2020, during the COVID-19 pandemic in Italy. All patients had a diagnosis of AD for a mean [SD] 12.8 [3.1] years. Baseline demographics, AD characteristics (EASI, cDLQI, NRS itch score, NRS sleep loss score) at baseline and week 16, and safety data were collected. Nineteen patients (52.6% men; mean [SD] age, 15.6 [1.4] years [range, 13-17 years]) were included in the analysis. All patients reached EASI-50 and 78.9% EASI-75, especially in those with EASI≥30 and BMI
- Published
- 2021